

CELLBXHEALTH plc
("CELLBXHEALTH", the "Company" or the "Group")
Update to Admission of Fundraising Shares

CELLBXHEALTH plc (AIM: CLBX), a leader in circulating tumour cell (CTC) intelligence announces, following the conclusion of the oversubscribed Placing, the following update with regards Admission of the Fundraising Shares.

Subject to the passing of the Resolutions, First Admission will be in respect of 9,090,000 First Tranche Fundraising Shares and is expected to occur at 8.00 a.m. on or around 16 December 2025. Second Admission will be in respect of up to 770,910,000 Second Tranche Placing Shares, the Subscription Shares and the Retail Offer Shares and is expected to occur at 8.00 a.m. on 18 December 2025 (or, in each case, such later time and/or date as Cavendish and the Company and Cavendish may agree, not (being no later than 8.00 a.m. on 16 January 2026).

Capitalised terms used but not defined in this announcement have the meanings given to them in the Launch Announcement, unless context provides otherwise.

For further information:

CellBxHealth plc	+44 (0) 1483 343434
Peter Collins, Chief Executive Officer	investor@CellBxHealth.com

Cavendish (NOMAD and Broker)	
Geoff Nash / Isaac Hooper / Hamza Munshi (Corporate Finance)	+44 (0) 20 7220 0500
Sunila de Silva (Corporate Broking)	
Nigel Birks (Life Science Specialist Sales)	

FTI Consulting	
Simon Conway, Ciara Martin, Sam Purewal	+44 (0) 203 727 1000

This Announcement is for information purposes only and does not constitute an offer to sell or issue or the solicitation of an offer to buy, acquire or subscribe for shares in the capital of the Company in the United States, Australia, Canada, Japan or the Republic of South Africa or any other jurisdiction where such offer or solicitation may be restricted, unlawful or unauthorised. Any failure to comply with these restrictions may constitute a violation of the securities laws of such jurisdictions. Subject to certain exemptions, the securities referred to herein may not be offered or sold in Canada, Australia, Japan or the Republic of South Africa or to, or for the account or benefit of any national resident or citizen of Canada, Australia, Japan or the Republic of South Africa. The Ordinary Shares have not been and will not be registered under the Securities Act of 1933, as amended (the "Securities Act") or the securities laws of any other jurisdiction of the United States, and may not be offered, sold or transferred, directly or indirectly, in the United States absent registration under the Securities Act or an available exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and the securities laws of any other jurisdiction of the United States. No public offering of the shares referred to in this Announcement is being made in the United States, United Kingdom, Australia, Canada, Japan, the Republic of South Africa or elsewhere.

About CellBxHealth plc

CellBxHealth plc is a CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology. Its patent-protected Parsortix® platform harvests CTCs from blood and can be seamlessly integrated with existing laboratory instruments for comprehensive downstream analysis - including whole-cell imaging, proteomic profiling and full genomic workflows.

Commercial activities centre on (1) Product Sales: Accelerating Parsortix platform adoption and consumable sales through CROs and clinical lab partnerships. (2) Lab Developed Tests (LDTs): Strategic partnerships combined with a focused in-house development programme. (3) Laboratory services: Clinical trial support and assay development.*

The product portfolio comprises the Parsortix® platform with associated consumables and assays. Laboratory services are delivered from CellBxHealth's GCLP certified UK laboratory, providing bespoke clinical-trial support and assay development.

For more information, visit <https://cellbxhealth.com/>.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

IOEFZMZMNKGKZM